CD274 and non-small cell lung carcinoma: The DARWIN clinical trial aims to evaluate whether targeting a clonal versus subclonal mutation with the anti-PD-L1 drug atezolizumab alters progression-free survival in patients with non-small-cell lung cancer (NCT02183883).